{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T15:06:57Z","timestamp":1792336017752,"version":"4.4.0"},"reference-count":28,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"abstract":"<jats:p>Tumor lysis syndrome (TLS) is a potentially lethal complication of anticancer treatment. It is caused by the rapid death of malignant cells after initiation of cytotoxic therapy and is typically observed in patients with bulky or highly proliferative malignancies. Currently, rasburicase is one of the recommended therapies for this oncologic emergency. Although this drug is generally well tolerated among patients, there have been several reports of hemolytic anemia following rasburicase infusions. With drug-induced hemolytic anemia, the condition usually resolves shortly after the offending agent is discontinued. However, anemia that is prolonged or severe can lead to problems such as splenomegaly and rapid heart rate. This paper will review primary literature identified through PubMed, International Pharmaceutical Abstracts, and Embase concerning the incidence of hemolytic anemia with rasburicase use. From the available data, the occurrence of hemolytic anemia will be discussed.<\/jats:p>","DOI":"10.5863\/1551-6776-19.4.310","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T19:43:12Z","timestamp":1603827792000},"page":"310-316","source":"Crossref","is-referenced-by-count":6,"title":["Hemolytic Anemia Following Rasburicase Administration: A Review of Published Reports"],"prefix":"10.5863","volume":"19","author":[{"given":"Annhien P.","family":"Nguyen","sequence":"first","affiliation":[{"name":"1Target, Fort Wayne, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve L.","family":"Ness","sequence":"additional","affiliation":[{"name":"2Christy Houston Foundation Drug Information Center, Belmont University College of Pharmacy, Nashville, Tennessee"},{"name":"3 Department of Pharmaceutical, Social and Administrative Sciences, Belmont University College of Pharmacy, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"12","key":"i1551-6776-19-4-310-b1","series-title":"Haematologica.","first-page":"1877","article-title":"Consensus conference on the management of tumor lysis syndrome","volume":"93","year":"2008","unstructured":"Tosi\n              P\n            , BarosiG, LazzaroC, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica.2008;93(12):1877\u20131885."},{"issue":"16","key":"i1551-6776-19-4-310-b2","series-title":"J Clin Oncol","first-page":"2767","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","year":"2008","unstructured":"Coiffier\n              B\n            , AltmanA, PuiCH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol2008;26(16):2767\u20132778."},{"issue":"3","key":"i1551-6776-19-4-310-b3","series-title":"Proc (Bayl Univ Med Cent).","first-page":"275","article-title":"Rasburicase (Elitek): a novel agent for tumor lysis syndrome","volume":"18","year":"2005","unstructured":"Ueng\n              S.\n            \n          \n          Rasburicase (Elitek): a novel agent for tumor lysis syndrome. Proc (Bayl Univ Med Cent).2005;18(3):275\u2013279."},{"issue":"2","key":"i1551-6776-19-4-310-b4","series-title":"Arch Intern Med.","first-page":"198","article-title":"Hyperuricemia complicating leukemia treatment with allopurinol and dialysis","volume":"123","year":"1969","unstructured":"Maher\n              JF\n            , RathCE, SchreinerGE.\n          Hyperuricemia complicating leukemia treatment with allopurinol and dialysis. Arch Intern Med.1969;123(2):198\u2013200."},{"issue":"3","key":"i1551-6776-19-4-310-b5","series-title":"J Clin Oncol.","first-page":"697","article-title":"Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma","volume":"19","year":"2001","unstructured":"Pui\n              C\n            , MahmoudHH, WileyJM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol.2001;19(3):697\u2013704."},{"key":"i1551-6776-19-4-310-b6","article-title":"Rasburicase product approval information","unstructured":"Food and Drug Administration. Rasburicase product approval information. http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/ucm080525.htm. Accessed October 20, 2013."},{"key":"i1551-6776-19-4-310-b7","article-title":"Drug information: Elitek (rasburicase)","unstructured":"CenterWatch. Drug information: Elitek (rasburicase). http:\/\/www.centerwatch.com\/drug-information\/fda-approvals\/drug-details.aspx?DrugID=1068. Accessed October 20, 2013."},{"key":"i1551-6776-19-4-310-b8","series-title":"Elitek (Rasburicase)","year":"Jan 2011","unstructured":"Product Information. Elitek (Rasburicase). Bridgewater, NJ: Hospira Inc, Jan 2011."},{"issue":"11","key":"i1551-6776-19-4-310-b9","series-title":"Am Fam Physician.","first-page":"2599","article-title":"Hemolytic anemia","volume":"69","year":"2004","unstructured":"Dhaliwal\n              G\n            , CornettPA, TierneyLM.\n          Hemolytic anemia. Am Fam Physician.2004;69(11):2599\u20132606."},{"issue":"1","key":"i1551-6776-19-4-310-b10","series-title":"Int J Clin Pharm.","first-page":"58","article-title":"Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia","volume":"33","year":"2011","unstructured":"Bauters\n              T\n            , MondelaersV, RobaysH, et al. Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia. Int J Clin Pharm.2011;33(1):58\u201360."},{"issue":"1","key":"i1551-6776-19-4-310-b11","series-title":"Pediatr Blood Cancer.","first-page":"189","article-title":"Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma\/leukemia","volume":"50","year":"2008","unstructured":"Borinstein\n              SC\n            , XuM, HawkinsDS.\n          Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma\/leukemia. Pediatr Blood Cancer.2008;50(1):189."},{"issue":"1","key":"i1551-6776-19-4-310-b12","series-title":"Pediatrics.","first-page":"e309","article-title":"Lethal effect of a single dose of rasburicase in a preterm newborn infant","volume":"131","year":"2013","unstructured":"Zaramella\n              P\n            , De SalviaA, ZaninottoM, et al. Lethal effect of a single dose of rasburicase in a preterm newborn infant. Pediatrics.2013;131(1):e309\u2013312."},{"issue":"4","key":"i1551-6776-19-4-310-b13","series-title":"Int J Hematol.","first-page":"492","article-title":"A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome","volume":"90","year":"2009","unstructured":"Kikuchi\n              A\n            , KigasawaH, TsurusawaM, et al. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome. Int J Hematol.2009;90(4):492\u2013500."},{"issue":"10","key":"i1551-6776-19-4-310-b14","series-title":"Blood.","first-page":"2998","article-title":"A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis","volume":"97","year":"2001","unstructured":"Goldman\n              SC\n            , HolcenbergJS, FinklesteinJZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood.2001;97(10):2998\u20133003."},{"issue":"1","key":"i1551-6776-19-4-310-b15","series-title":"Clin J Oncol Nurs.","first-page":"12","article-title":"Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome","volume":"6","year":"2002","unstructured":"Brant, JM.\n          \n          Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome. Clin J Oncol Nurs.2002;6(1):12\u201316."},{"key":"i1551-6776-19-4-310-b16","series-title":"The Merck Manual of Diagnosis & Therapy [book online]","article-title":"Anemias caused by hemolysis","year":"2011","unstructured":"Anemias caused by hemolysis. In: PorterRS, ed. The Merck Manual of Diagnosis & Therapy [book online]. 19th ed. Jackson, WY: Merck & Co Inc; 2011. STAT!Ref Online Electronic Medical Library. http:\/\/online.statref.com. Accessed November 11, 2013."},{"key":"i1551-6776-19-4-310-b17","series-title":"Hematology Am Soc Hematol Educ Program.","first-page":"73","article-title":"Drug-induced immune hemolytic anemia","year":"2009","unstructured":"Garratty\n              G.\n            \n          \n          Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program.2009:73\u201379."},{"key":"i1551-6776-19-4-310-b18","series-title":"Internal Medicine [book online]","article-title":"Hemolytic anemia","year":"1998","unstructured":"Winkelmann\n              JC.\n            \n          \n          Hemolytic anemia. In: SteinJH, ed. Internal Medicine [book online]. 5th ed. Jackson, WY: Mosby Inc; 1998. STAT!Ref Online Electronic Medical Library. http:\/\/online.statref.com. Accessed November 17, 2013."},{"key":"i1551-6776-19-4-310-b19","series-title":"Identifying adverse drug reactions","article-title":"Texas Department of Aging and Disability Services","unstructured":"Texas Department of Aging and Disability Services. Identifying adverse drug reactions. http:\/\/qmweb.dads.state.tx.us\/MedSim\/Naranjo.htm. Accessed November 19, 2013."},{"issue":"1","key":"i1551-6776-19-4-310-b20","series-title":"Mater Med Pol.","first-page":"60","article-title":"Acute pancreatitis after Imuran in a patient with autoimmune haemolytic anaemia","volume":"10","year":"1978","unstructured":"Niederle\n              B\n            , BartosV, HrodekO, Hyniov\u00e1H.\n          Acute pancreatitis after Imuran in a patient with autoimmune haemolytic anaemia. Mater Med Pol.1978;10(1):60\u201362."},{"key":"i1551-6776-19-4-310-b21","series-title":"Nihon Shokakibyo Gakkai Zasshi.","first-page":"698","article-title":"Case of autoimmune pancreatitis accompanied by autoimmune hemolytic anemia [in Japanese]","volume":"106","year":"2009","unstructured":"Yokomichi\n              H\n            , NakaharaT, AsamotoY, et al. Case of autoimmune pancreatitis accompanied by autoimmune hemolytic anemia [in Japanese]. Nihon Shokakibyo Gakkai Zasshi.2009;106:698\u2013705."},{"key":"i1551-6776-19-4-310-b22","series-title":"The Merck Manual of Diagnosis & Therapy [book online]","article-title":"Appendix II: normal laboratory values","year":"2011","unstructured":"Appendix II: normal laboratory values. In: PorterRS, eds. The Merck Manual of Diagnosis & Therapy [book online]. 19th ed. Jackson, WY: Merck & Co Inc; 2011. STAT!Ref Online Electronic Medical Library. http:\/\/online.statref.com. Accessed Nov 19, 2013."},{"issue":"6","key":"i1551-6776-19-4-310-b23","series-title":"Am Fam Physician.","first-page":"1153","article-title":"Urinalysis: a comprehensive review","volume":"71","year":"2005","unstructured":"Simerville\n              JA\n            , MaxtedWC, PahiraJJ.\n          Urinalysis: a comprehensive review. Am Fam Physician.2005;71(6):1153\u20131162."},{"issue":"4","key":"i1551-6776-19-4-310-b24","series-title":"Pediatrics.","first-page":"1444","article-title":"The Apgar score","volume":"117","year":"2006","unstructured":"American Academy of Pediatrics, Committee on Fetus and Newborn, American College of Obstetricians and Gynecologists and Committee on Obstetric Practice. The Apgar score. Pediatrics.2006;117(4):1444\u20131447."},{"key":"i1551-6776-19-4-310-b25","series-title":"Care of the Newborn","year":"2004","unstructured":"Sing\n              M\n            \n          , ed. Care of the Newborn. 6th ed. New Delhi, India: Sagar Publications; 2004."},{"issue":"8","key":"i1551-6776-19-4-310-b26","series-title":"Indian J Pediatr.","first-page":"821","article-title":"Urinary uric acid in preterm neonates","volume":"76","year":"2009","unstructured":"Basu\n              P\n            , SomS, ChoudhuriN, et al. Urinary uric acid in preterm neonates. Indian J Pediatr.2009;76(8):821\u2013823."},{"issue":"4","key":"i1551-6776-19-4-310-b27","series-title":"J Oncol Pharm Pract.","first-page":"425","article-title":"Methemoglobinemia induced by rasburicase in a pediatric patient: a case report and literature review","volume":"18","year":"2012","unstructured":"Ng\n              JS\n            , EdwardsEM, EgelundTA.\n          Methemoglobinemia induced by rasburicase in a pediatric patient: a case report and literature review. J Oncol Pharm Pract.2012;18(4):425\u2013431."},{"key":"i1551-6776-19-4-310-b28","article-title":"Glucose-6-phosphate dehydrogenase deficiency","unstructured":"University of Maryland Medical Center. Glucose-6-phosphate dehydrogenase deficiency. http:\/\/umm.edu\/health\/medical\/ency\/articles\/glucose6phosphate-dehy-drogenase-deficiency. Accessed October 27, 2013."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/19\/4\/article-p310.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/19\/4\/310\/1786711\/1551-6776-19_4_310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/19\/4\/article-p310.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/19\/4\/article-p310.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:42:57Z","timestamp":1747356177000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/19\/4\/article-p310.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":28,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-19.4.310","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}